Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nektar Doses First Patients in Neuropathic Pain Study | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Nektar Doses First Patients in Neuropathic Pain Study

Testing pharmacokinetics of novel pain-blocker

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Nektar Therapeutics has dosed the first subjects in a Phase I study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain. The single-ascending dose study will assess its MKTR-171’s pharmacokinetics, tolerability, and safety in as many as 50 healthy subjects.  

NKTR-171 is a new molecular entity that is specifically designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system. NKTR-171 is designed to be a peripherally-restricted molecule that  selectively blocks hyper-excitable sodium channels without causing the CNS side effects that limit usage of existing therapies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics